Professional Title & Qualifications:
-
Chief Physician,
-
Professor,
-
Doctoral Supervisor
Specialization:
Hospital & Department：
Peking University First Hospital – Department of Nuclear Medicine
(address: No. 8 Xishiku Street, Xicheng District, Beijing, 100034)
Dr. Lei Kang (康磊) - Nuclear Medicine Physician
Personal Biography
-
Dr. Lei Kang serves as the Director of the Department of Nuclear Medicine at Peking University First Hospital and is the Party Branch Secretary.
-
He is a recognized Beijing Outstanding Young Scientist and a Beijing Science and Technology Nova.
-
In clinical practice, he is highly proficient in executing PET and SPECT examinations, writing and reviewing clinical reports, and administering targeted nuclear medicine therapies such as radioactive iodine treatments.
-
Alongside his clinical work, Dr. Kang is deeply committed to molecular imaging research, focusing on the innovation of tumor-targeted tracing and in-vivo evaluation techniques.
-
Leveraging specific biomarkers and the non-invasive nature of radionuclides, he has independently designed and constructed a series of novel tumor-targeted radioactive molecular probes with independent intellectual property rights.
Why Choose Dr. Lei Kang?
Dr. Lei Kang is a globally recognized pioneer in targeted radionuclide therapies, specifically excelling in Iodine-131 treatments for thyroid conditions and advanced therapies (Sr-89, Ra-223) for bone metastases. Having successfully managed cases for over 1,700 patients, his immense clinical volume provides him with unparalleled expertise in handling complex, refractory conditions that require precise, personalized nuclear interventions.
Bridging the gap between Western medical standards and China's cutting-edge clinical applications, Dr. Lei Kang completed extensive fellowship training at the University of Wisconsin-Madison and the UCLA Ronald Reagan Medical Center PET Center. As a leading investigator with nearly 100 SCI publications in top-tier international journals , he offers patients access to state-of-the-art tumor-targeted tracing and innovative in-vivo evaluation techniques that represent the absolute forefront of global molecular imaging.
Secure Your Remote Written Consultation
Traveling across the globe for medical care is a significant decision. Before committing to international travel, we strongly encourage you to arrange a remote written consultation with Dr. Lei Kang. Through MedBridgeNZ, our Clinical Patient Care Team will securely organize and submit your current medical records for his expert evaluation.
You will receive a comprehensive written second opinion report within a few working days. This crucial pre-travel assessment clarifies your eligibility for advanced nuclear medicine therapies and ensures that traveling to China is the most appropriate medical pathway for your specific diagnosis.
Disclaimer: MedBridgeNZ is a dedicated medical concierge provider. We do not provide direct medical advice, diagnosis, or treatment. All clinical evaluations and treatment plans are determined exclusively by the attending physician.
Book an online consultation with Dr. Lei Kang
Home > Specialists > Nuclear Medicine > Dr. Lei Kang (康磊)
Areas of Expertise
-
Iodine-131 (I-131) therapy for hyperthyroidism and thyroid cancer.
-
Strontium-89 (Sr-89) and Radium-223 (Ra-223) treatments for bone metastases.
-
Diagnosis and comprehensive treatment of various thyroid diseases.
-
Advanced PET/CT imaging consultations.
Verified Patient Satisfaction Metrics
⭐⭐⭐⭐⭐ 5.0/5.0 Overall Rating
-
5.0/5.0 Clinical Outcome Satisfaction
-
5.0/5.0 Bedside Manner & Professionalism
-
(Source: Statistics based on verified clinical outcomes and patient feedback logs from domestic medical registries.)
High Demand: Chosen by over 1,800 patients online for consultation and second opinions.
Work Experience
-
Jan 2022 – Present: Doctoral Supervisor, Department of Nuclear Medicine, Peking University First Hospital.
-
May 2020 – Present: Master's Supervisor, Department of Nuclear Medicine, Peking University First Hospital.
-
Aug 2019 – Present: Associate Professor and Associate Chief Physician (Currently Chief Physician), Department of Nuclear Medicine, Peking University First Hospital.
-
Aug 2015 – Jul 2019: Attending Physician, Department of Nuclear Medicine, Peking University First Hospital.
-
Aug 2010 – Jul 2015: Resident Physician, Department of Nuclear Medicine, Peking University First Hospital.
Education & Fellowship
-
Jan 2017 – Jan 2018: Visiting Scholar/Fellow, Department of Radiology and Biomedical Engineering, University of Wisconsin-Madison, USA (Mentor: Prof. Weibo Cai).
-
Sep 2016 – Dec 2022: Visiting Scholar/Fellow, PET Center, Ronald Reagan Medical Center, University of California, Los Angeles (UCLA), USA (Mentor: Prof. Johannes Czernin).
Professional Memberships
-
Member of the Chinese Medical Association.
-
Director, Youth Council of the China Photosensitive Society.
-
Member, Clinical Diagnosis Working Group, Nuclear Medicine Physicians Branch of the Chinese Medical Doctor Association.
-
Editorial Board Member, 1st Youth Editorial Board of the Chinese Journal of Clinical Oncology.
-
Deputy Group Leader, Radiopharmacy and Labeled Compounds Professional Group, Nuclear Chemistry and Radiochemistry Branch of the Chinese Nuclear Society.
-
Expert, Standardized Residency Training Examination Question Bank Construction, National Health Commission.
-
Member of the PET Group, Translational Medicine Imaging Professional Committee, and Solid Target Nuclide Working Committee, Nuclear Medicine Branch of the Chinese Medical Association.
-
Member, Nuclear Medicine Professional Group, Tumor Imaging Professional Committee of the Chinese Anti-Cancer Association.
-
Youth Member, Nuclear Medicine Branch of the Chinese Nuclear Society and Chinese Society of Medical Imaging Technology.
-
Deputy Group Leader, External Relations and Radiation Protection Group, Nuclear Medicine Branch of the Beijing Medical Association.
Honors & Awards
-
Beijing Outstanding Young Scientist of Natural Science Foundation & Beijing Science and Technology Nova.
-
Xiao Lun Youth Science and Technology Award (A premier award in Chinese nuclear medicine).
-
1st Place globally for the CMIIT Young Investigator Award at the 2019 SNM Annual Meeting.
-
Candidate for the Top Poster Award in Molecular Targeted Probes at the 68th SNMMI Annual Meeting.
-
2018 SNM Travel Award and 1st Place in the 2018 SNM English Speech Contest (Beijing Division).
-
Excellent Teacher of Peking University First Hospital (2020-2021).
-
Peking University Excellent Doctoral Dissertation Award and Peking University First Hospital Research Star of Hope.
Research & Publications
-
Served as first or corresponding author for nearly 100 SCI papers, including 22 papers with an Impact Factor (IF) > 10 and 45 papers with an IF > 5.
-
Published in top-tier authoritative journals such as Advanced Science, Nat Commun, Proc Natl Acad Sci, J Clin Invest, J Am Chem Soc, J Nucl Med, and Eur J Nucl Med Mol I.
-
Led 15 national and municipal research projects, including grants from the National Natural Science Foundation of China, Beijing Science and Technology Nova Talent Plan, and the Ministry of Education.
-
Holds 1 granted national patent, with 3 additional national patents and 1 US patent pending.
-
Co-authored two core textbooks on Nuclear Medicine published by the People's Medical Publishing House for five-year and eight-year medical programs.
Academic Profiles & Credentials
Verify Dr. Kang's academic identity, research contributions, and peer-reviewed publications through the official international registries below:
-
ORCID Profile: Official registry confirming Dr. Lei Kang's extensive research portfolio, clinical trials, and academic affiliations in Nuclear Medicine and Molecular Imaging.
- PubMed Author Profile: Comprehensive database of Dr. Kang’s peer-reviewed clinical studies and indexed medical publications.
Selected Peer-Reviewed Publications
Below is a selection of Dr. Kang's highly cited clinical research, demonstrating ongoing leadership in the treatment and diagnostic evaluation of complex conditions:
-
Gu, T., et al. (2025). B-cell maturation antigen targeted PET/CT imaging in multiple myeloma: a first-in-human study. Journal of Hematology & Oncology. Read on PubMed (PMID: 41239440)
-
Huang, W., et al. (2024). CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies. European Journal of Nuclear Medicine and Molecular Imaging. Read on PubMed (PMID: 39725695)
-
Liu, Y., et al. (2024). Primary mesenchymal tumors of the prostate: 18F FDG PET/CT findings. EJNMMI Research. Read on PubMed (PMID: 39542970)
*The doctor’s information is sourced from the hospital’s official website or provided directly by the doctor. Due to update cycles, there may be occasional delays in reflecting the most recent changes.
Frequently Asked Questions (FAQs)
How can I consult with Dr. Lei Kang before traveling to China?
You can easily arrange a remote written consultation through MedBridgeNZ without leaving your home. Simply reply to our team with your current medical records, and we will facilitate a thorough case review with Dr. Lei Kang. You will receive a detailed written second opinion report in just a few working days, empowering you to make an informed, data-driven decision.
Is Dr. Lei Kang the right specialist for my condition?
Dr. Lei Kang specializes heavily in Iodine-131 therapy for thyroid cancer and hyperthyroidism, as well as targeted treatments for bone metastases. When you submit your files for a Free Assessment, our Clinical Patient Care Team will first verify if his specific molecular imaging and nuclear medicine expertise aligns with your exact medical needs before proceeding.
How much will the actual treatment cost in Beijing?
Precise treatment cost estimates can only be provided after a doctor's consultation. Once Dr. Lei Kang reviews your medical files and outlines a highly personalized medical pathway in your written second opinion report, our concierge team will help you understand all anticipated clinical and logistical expenses associated with the treatment.
Do I need to arrange my own hospital appointments and travel logistics?
No, you do not have to navigate a foreign healthcare system alone. We serve clients globally and handle all on-the-ground coordination. Once your treatment plan is confirmed, we manage everything from scheduling your priority face-to-face appointments at Peking University First Hospital to arranging medical visas, accommodation, and providing expert bilingual medical accompaniment throughout your stay.
How MedBridgeNZ Helps You:
MedBridgeNZ is your dedicated medical concierge. We do not provide medical advice but handle all logistics to ensure you receive care from experts like Dr. Lei Kang. Our services include appointment booking, visa assistance, travel arrangements, and translation services for a stress-free medical trip to China.